Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Explore the many benefits of having a premium branded profile on Glassdoor, like increased influence and advanced analytics. Aandeel Alexion Pharmaceuticals OTC:ALXN, US0153511094 Vertraagde koers Settlement koers (usd) 155,700 1 feb 2021 22:00 Verschil +2,370 (+1,55%) Dagrange 155,500 - 156,770 But that’s not new. The company’s stock price has collected 1.49% of gains in the last five trading sessions. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) went up by 1.70% from its latest closing price compared to the recent 1-year high of $162.60. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images), How China Aims To Beat The U.S., Europe At ‘Net Zero’ Carbon, How China’s Solar Industry Is Set Up To Be The New Green OPEC, Aggressive Investing Is Not What You Think It Is, The S&P Is Likely Moving Higher In This Week, It’s Time: Set Your Investment Clock Forward As New Stock Market Winners Dawn. [LONDON] AstraZeneca, one of the drugmakers leading the fight against Covid-19, highlighted where its growth will come from after the pandemic with a US$39 billion deal for rare-disease specialist Alexion Pharmaceuticals. But Consistent Performance Could Change Investor Perspective. See insights on Alexion Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, effective immediately. Alexion Pharmaceuticals stock hasn’t moved much this year. 2, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Total assets can be defined as the sum of all assets on a company's balance sheet. © 2021 Forbes Media LLC. All answers shown come directly from Alexion Pharmaceuticals Reviews and are not edited or altered. 20, 2020-- Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS ® (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS). Firstly, pricing is usually very high (Soliris costs roughly $600k per year, for example) and insurers typically bear these expenses. Alexion Pharmaceuticals was part of our Out Of Favor Health Care Stocks theme, which includes healthcare and pharma companies that have shown strong historical revenue growth, improving fundamentals, and yet have not rallied much. It could be argued whether the price that Alexion paid for acquisitions made sense or not, but there is no denying that underlying financials have improved. It has outperformed the broader market year after year, consistently. The Securities and Exchange Commission today announced that Boston-based pharmaceutical company Alexion Pharmaceuticals Inc. has agreed to pay more than $21 million to resolve charges that it violated the books and records and internal accounting controls provisions of the … Wall Street expects a year-over-year decline in earnings on higher revenues when Alexion Pharmaceuticals (ALXN) reports results for the quarter ended June 2020. Raadpleeg hier de meest recente koersen, grafieken, financiële data, bedrijfsgegevens en nieuws over het aandeel Alexion Pharmaceuticals This might include you though you may have invested money in these companies, or may have been working with one of them for years as an employee, or have consulted with them as an expert for a long time. Considering that the pharma industry thrives on innovation and R&D, relying on acquisition for growth hasn’t gone down well with investors. The company’s revenue has grown consistently, increasing from $3.6 billion in 2017 to almost $5 billion in 2019. AstraZeneca Plc will acquire U.S. based Alexion Pharmaceuticals in a US$39 billion deal, the company said in a statement on Saturday. The platform uses extensive data to show in a single snapshot what drives the value of a company's business. In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, Connecticut, not far from the company'… Our dashboard What Factors Drove 7.8% Change In Alexion Pharmaceuticals Stock Between 2018 And Now? Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. ALXN Arbutus Biopharma - Wikipedia On May 6, 2015, Alexion Pharmaceuticals (nasdaq: ALXN) and Synageva announced that they entered into a definitive agreement in which Alexion would acquire Synageva for a value of $230 per share. All content is posted anonymously by employees working at Alexion Pharmaceuticals. Alexion Pharmaceuticals' P/E ratio would be typical for a company that's expected to deliver solid growth, ... chief EM Asia and Europe strategist at TD Securities Ltd. in Singapore. Poh Lam Ong at Singapore. Now the deal values Alexion stock at about $175 per share, a premium of around 45% over Friday’s close. Thank you for your request. For more such companies and the detailed selection criteria, view our theme Out Of Favor Health Care Stocks, [Updated 8/28/20] Alexion Pharmaceuticals: Good Growth But Out Of Favor. Since 2013, Alexion’s facility in Blanchardstown, Dublin has served as the Company’s Global Supply Chain and Operations headquarters. The data is not intended for trading purposes. ALEXION PHARMACEUTICALS, INC. TABLE 1: CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in millions, except per share amounts) (unaudited) Three months ended Twelve months ended December 31, December 31, 2019 2018 2019 2018. Zoek naar vacatures bij Alexion Pharmaceuticals. Microbiology Supervisor at Alexion Pharmaceuticals, Inc. Singapore 500+ connections. The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya ® in Europe , to Alexion’s commercial … If we look at the last twelve months, the figure stands at over $5.5 billion. Will Snowflake’s $20M Investment In ThoughtSpot Pay Off. Glassdoor will not work properly unless browser cookie support is enabled.Learn how to enable cookies. Alexion is collaborating with Caelum Biosciences to develop CAEL-101 for … - a company that is best known for its Soliris and Ultomiris drugs which are used to treat rare blood disorders - in a cash and stock deal valued at about $39 billion. Search alexion pharmaceuticals jobs. Alexion Pharmaceuticals (ALXN) is a stock many investors are watching right now. A Sales Representative will be in contact with you with your custom quote. What is health insurance like at Alexion Pharmaceuticals? Our culture is rooted in integrity, inclusiveness, and our, Our mission is to transform the lives of people living with rare and devastating diseases through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. So, Alexion might give good returns from current levels. Glassdoor gives you an inside look at what it's like to work at Alexion Pharmaceuticals, including salaries, reviews, office photos, and more. BOSTON--(BUSINESS WIRE)--Apr. Copyright © 2008–2021, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Customise your profile with branded content, People living with rare and devastating diseases are our Guiding Star. Tell us who you are and a Glassdoor Sales Representative will get back to you right away. Alexion Pharmaceuticals total assets from 2006 to 2020. REUTERS: AstraZeneca shares fell 9per cent on Monday, as investors moved to price in the British drugmaker's US$39 billion deal for U.S. biotech firm Alexion Pharmaceuticals… Alexion Pharmaceuticals total assets for the quarter ending December 31, 2020 were $18.103B, a 3.18% increase year-over-year. Follow the latest news and comprehensive coverage on ALEXION PHARMACEUTICALS at CNA Investors Jennifer Zibuda, IR@portola.com. Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you touch, read, or hear about everyday, impact its stock price. You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. Opinions expressed by Forbes Contributors are their own. But if these acquisitions eventually pan out, there is the potential to unlock a lot of value. It spent nearly $4 billion in the last 3 years acquiring multiple drug companies. ALXN | Complete Alexion Pharmaceuticals Inc. stock news by MarketWatch. The market expects Alexion Pharmaceuticals (ALXN) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended March 2020. Alexion’s global headquarters is in Boston, Massachusetts and its Center of Excellence is based in New Haven, Connecticut. ALXN is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Get the right alexion pharmaceuticals job with company ratings & salaries. Reporting to Chief Executive Officer, Ludwig Hantson will be: John Orloff, M.D., Executive Vice President, Head of Research & Development, Anne-Marie Law, Executive Vice President, Chief Human Resources Officer, and Indrani Lall Franchini, J.D., Executive Vice President, Chief Compliance Officer. In addition, Alexion’s EBITDA Margin increased from 38.5% in 2017 to 54.8% in 2019, implying a 42.3% jump. Alexion Pharmaceuticals Inc. for $39 billion in cash and shares, adding a specialist in the treatment of rare diseases and immunology to its portfolio of medications for cancer and other illnesses. Jose Sanchez GM Site Head at Biogen Singapore. However, underlying financials suggest a different story. See all Trefis Price Estimates and Download Trefis Data here, What’s behind Trefis? Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) was in 57 hedge funds' portfolios at the end of June. Get hired! United Kingdom. Any preference about using R or SAS; Why you choose this company; Ask them some questions in the end; ....... 9 Attention-Grabbing Cover Letter Examples, 10 of the Best Companies for Working From Home, The Top 20 Jobs With the Highest Satisfaction, 12 Companies That Will Pay You to Travel the World, 7 Types of Companies You Should Never Work For, How to Become the Candidate Recruiters Can’t Resist, 11 Words and Phrases to Use in Salary Negotiations, 10 High-Paying Jobs With Tons of Open Positions, Negotiating Over Email? This was partly due to the company’s acquisition spree, which has not gone down too well with investors. This is the Alexion Pharmaceuticals company profile. Poh Lam Ong. On Saturday morning, AstraZeneca announced an agreement to buy Alexion Pharmaceuticals (NASDAQ:ALXN) and its line of treatments for rare diseases for $39 billion in a combination of cash and stock. summarizes what has driven Alexion’s stock price in the last 2-3 years, making it clear that despite good financial performance, the market is not favoring it yet. First, introduce their summer internship position. You may opt-out by. Alexion Appoints Ludwig Hantson, Ph.D., as Chief Executive Officer. I interviewed at Alexion Pharmaceuticals (United States), Alexion Announces Additions to Executive Leadership Tea.css-epvm6{white-space:nowrap;}m. NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) today announced key additions to its executive leadership team effective June 5, 2017. Despite growing its EBITDA per share by nearly 100% since 2018, the company’s stock has increased less than 10% over that period. Alexion is focused on providing innovative treatments to patients with life-threatening rare diseases for which there are few, if any, effective treatment options. 102 vacatures bij Alexion Pharmaceuticals, inclusief informatie over salarissen, beoordelingen en reviews, geplaatst door werknemers van Alexion Pharmaceuticals. View real-time stock prices and stock quotes for a full financial overview. It appears that investors would have preferred for Alexion to spend the money on repurchase of shares instead of acquisitions. For general inquiries, please contact our Global Headquarters at 1-475-230-2596.. To report an adverse event experience for any Alexion product, please contact us at AdverseEventReporting@alexion.com or 1-844-259-6783.. To report an issue or complaint with an Alexion product, please contact us at ProductComplaints@alexion.com.. To report a compliance or … This could signal a buying opportunity. Here’s a top-quality portfolio to outperform the market, with over 100% return since 2016, versus 55% for the S&P 500. Source: Alexion Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. This is the Alexion Pharmaceuticals company profile. All Rights Reserved, This is a BETA experience. The company is also involved in immune system research related to autoimmune diseases. The Investor Relations website contains information about Alexion Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Here’s Exactly What to Write to Get Top Dollar, How To Follow Up After an Interview (With Templates! Alexion stock has been a laggard in the pharma space, largely moving sideways in recent years, despite posting strong growth (sales grew at an average of 17% each year over the last 5 years). See How It’s Powering New Collaboration and What-Ifs For CFOs and Finance Teams | Product, R&D, and Marketing Teams, Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company's products, that you. We believe it is our responsibility to listen to, understand, and change the lives of patients and those who work tirelessly to help them. Alexion Pharmaceuticals has 3,082 employees across 23 locations and $6.07 B in annual revenue in FY 2020. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images). I have been working at Alexion Pharmaceuticals full-time for more than 8 years, I applied online. BOSTON--(BUSINESS WIRE)--Jul. Alexion Pharmaceuticals total number of employees in 2020 was 3,837, a 24.5% increase from 2019.; Alexion Pharmaceuticals total number of employees in 2019 was 3,082, a 16.04% increase from 2018.; Alexion Pharmaceuticals total number of employees in 2018 was 2,656, a 5.19% increase … How to Answer: What Are Your Strengths and Weaknesses? Alexion is a global biopharmaceutical company focused on developing life-changing therapies for people living with rare disorders. The essence is that Alexion has grown its revenue consistently, with significant improvement in EBITDA margin in 2019 that has sustained this year as well. 13 matching reviews. Then ask about the project in the resume; And also some techniques they are interested in about the project. People living with rare diseases and devastating conditions are our inspiration and Guiding Star. Late last week, AstraZeneca said that it would acquire Alexion Pharmaceuticals 0.1 0.3 1.1 1.1 Despite this, its EV/EBITDA multiple has fallen from 20.6 in 2018 to 8.3 currently. Alexion Pharmaceuticals stock hasn’t moved much this year. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. EBITDA is a measure of operational profitability, not counting non-cash expenses such as depreciation and amortization. Alexion Pharmaceuticals is een Amerikaans farmaceutisch bedrijf gespecialiseerd in weesgeneesmiddelen voor zeldzame aandoeningen.. Activiteiten.